Rapid development of tolerance to the behavioural actions of cholecystokinin [15]

Jacqueline Crawley, M. C. Beinfeld

Research output: Contribution to journalArticle

197 Citations (Scopus)

Abstract

Cholecystokinin (CCK) acts acutely to inhibit food consumption in fasted rats1-4, mice5-7, sheep8, pigs9, monkeys10 and humans11-13. CCK has been proposed as a satiety signal, inducing the behavioural sequence of satiety2, or as an aversive internal stimulus, which inhibits food intake by inducing malaise4. Reductions in food intake and related exploratory behaviours are initiated by CCK at its peripheral receptor in the gut, which appears to transmit sensory feedback via the vagus nerve to brain regions mediating appetitive behaviours15-17. The therapeutic potential of CCK as an appetite suppressant in obesity syndromes rests on the demonstration of significant, long-lasting body weight reduction. Chronic CCK administration by repeated injections is problematic, since this peptide is rapidly degraded in vivo. We chose the Alzet constant infusion osmotic minipump to investigate possible alterations in body weight and food intake during continuous infusion of CCK. We now report that no change was detected in either body weight or total daily food consumption at any time point during 2 weeks of intraperitoneally (i.p.) infused CCK. The mechanism underlying the lack of chronic CCK effects appears to be a rapid development of behavioural tolerance. Acute challenge doses of CCK which induced satiety-related behaviours in saline-infused rats were ineffective in CCK-infused rats. The behavioural tolerance was apparent within a few hours of minipump implantation. These results provide the first evidence that rapid and reversible tolerance develops to the actions of a gut peptide.

Original languageEnglish (US)
Pages (from-to)703-706
Number of pages4
JournalNature
Volume302
Issue number5910
DOIs
StatePublished - 1983
Externally publishedYes

Fingerprint

Cholecystokinin
Eating
Body Weight
Food
Appetite Depressants
Sensory Feedback
Peptides
Exploratory Behavior
Vagus Nerve
Weight Loss
Obesity
Injections

ASJC Scopus subject areas

  • General

Cite this

Rapid development of tolerance to the behavioural actions of cholecystokinin [15]. / Crawley, Jacqueline; Beinfeld, M. C.

In: Nature, Vol. 302, No. 5910, 1983, p. 703-706.

Research output: Contribution to journalArticle

@article{50b525b7c0574968a74694f333693e29,
title = "Rapid development of tolerance to the behavioural actions of cholecystokinin [15]",
abstract = "Cholecystokinin (CCK) acts acutely to inhibit food consumption in fasted rats1-4, mice5-7, sheep8, pigs9, monkeys10 and humans11-13. CCK has been proposed as a satiety signal, inducing the behavioural sequence of satiety2, or as an aversive internal stimulus, which inhibits food intake by inducing malaise4. Reductions in food intake and related exploratory behaviours are initiated by CCK at its peripheral receptor in the gut, which appears to transmit sensory feedback via the vagus nerve to brain regions mediating appetitive behaviours15-17. The therapeutic potential of CCK as an appetite suppressant in obesity syndromes rests on the demonstration of significant, long-lasting body weight reduction. Chronic CCK administration by repeated injections is problematic, since this peptide is rapidly degraded in vivo. We chose the Alzet constant infusion osmotic minipump to investigate possible alterations in body weight and food intake during continuous infusion of CCK. We now report that no change was detected in either body weight or total daily food consumption at any time point during 2 weeks of intraperitoneally (i.p.) infused CCK. The mechanism underlying the lack of chronic CCK effects appears to be a rapid development of behavioural tolerance. Acute challenge doses of CCK which induced satiety-related behaviours in saline-infused rats were ineffective in CCK-infused rats. The behavioural tolerance was apparent within a few hours of minipump implantation. These results provide the first evidence that rapid and reversible tolerance develops to the actions of a gut peptide.",
author = "Jacqueline Crawley and Beinfeld, {M. C.}",
year = "1983",
doi = "10.1038/302703a0",
language = "English (US)",
volume = "302",
pages = "703--706",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "5910",

}

TY - JOUR

T1 - Rapid development of tolerance to the behavioural actions of cholecystokinin [15]

AU - Crawley, Jacqueline

AU - Beinfeld, M. C.

PY - 1983

Y1 - 1983

N2 - Cholecystokinin (CCK) acts acutely to inhibit food consumption in fasted rats1-4, mice5-7, sheep8, pigs9, monkeys10 and humans11-13. CCK has been proposed as a satiety signal, inducing the behavioural sequence of satiety2, or as an aversive internal stimulus, which inhibits food intake by inducing malaise4. Reductions in food intake and related exploratory behaviours are initiated by CCK at its peripheral receptor in the gut, which appears to transmit sensory feedback via the vagus nerve to brain regions mediating appetitive behaviours15-17. The therapeutic potential of CCK as an appetite suppressant in obesity syndromes rests on the demonstration of significant, long-lasting body weight reduction. Chronic CCK administration by repeated injections is problematic, since this peptide is rapidly degraded in vivo. We chose the Alzet constant infusion osmotic minipump to investigate possible alterations in body weight and food intake during continuous infusion of CCK. We now report that no change was detected in either body weight or total daily food consumption at any time point during 2 weeks of intraperitoneally (i.p.) infused CCK. The mechanism underlying the lack of chronic CCK effects appears to be a rapid development of behavioural tolerance. Acute challenge doses of CCK which induced satiety-related behaviours in saline-infused rats were ineffective in CCK-infused rats. The behavioural tolerance was apparent within a few hours of minipump implantation. These results provide the first evidence that rapid and reversible tolerance develops to the actions of a gut peptide.

AB - Cholecystokinin (CCK) acts acutely to inhibit food consumption in fasted rats1-4, mice5-7, sheep8, pigs9, monkeys10 and humans11-13. CCK has been proposed as a satiety signal, inducing the behavioural sequence of satiety2, or as an aversive internal stimulus, which inhibits food intake by inducing malaise4. Reductions in food intake and related exploratory behaviours are initiated by CCK at its peripheral receptor in the gut, which appears to transmit sensory feedback via the vagus nerve to brain regions mediating appetitive behaviours15-17. The therapeutic potential of CCK as an appetite suppressant in obesity syndromes rests on the demonstration of significant, long-lasting body weight reduction. Chronic CCK administration by repeated injections is problematic, since this peptide is rapidly degraded in vivo. We chose the Alzet constant infusion osmotic minipump to investigate possible alterations in body weight and food intake during continuous infusion of CCK. We now report that no change was detected in either body weight or total daily food consumption at any time point during 2 weeks of intraperitoneally (i.p.) infused CCK. The mechanism underlying the lack of chronic CCK effects appears to be a rapid development of behavioural tolerance. Acute challenge doses of CCK which induced satiety-related behaviours in saline-infused rats were ineffective in CCK-infused rats. The behavioural tolerance was apparent within a few hours of minipump implantation. These results provide the first evidence that rapid and reversible tolerance develops to the actions of a gut peptide.

UR - http://www.scopus.com/inward/record.url?scp=0020522487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020522487&partnerID=8YFLogxK

U2 - 10.1038/302703a0

DO - 10.1038/302703a0

M3 - Article

C2 - 6300693

AN - SCOPUS:0020522487

VL - 302

SP - 703

EP - 706

JO - Nature

JF - Nature

SN - 0028-0836

IS - 5910

ER -